SPECTRAL ENERGIES LLC — Department of Defense SBIR Phase I: CBD181-006

Description

We propose a novel two-dimensional mass spectrometry (2D-MS) technique based on ion trap arrays to identify illicit and designer drugs. This approach will give an unprecedented multiplex advantage for miniature mass spectrometry, allowing novice field technicians to rapidly identify drugs affecting the central nervous system based on both the m/z ratio and fragmentation pattern of an ion. Towards this aim, we will develop a proof-of-principles testing platform in Phase I to demonstrate (1) pairing of a 36-element ion trap array with a discontinuous ionization source and paper spray ionization (PSI), (2) control of the secular frequency of an ion by systematically changing the trap geometry, and (3) position-sensitive detection from the ion trap array. The instrument constructed in Phase I will evolve into a 2D-MS prototype instrument in Phase II by using an imaging microchannel plates detector to obtain the full 2D mass spectrum. Because 2D-MS will provide an all-in-one measurement of product ion, precursor ion, and neutral loss scans for all ions simultaneously, a field technician will identify drugs based on a computer automated library analysis of these data. Therefore, our measurement will minimize knowledge, training, and interpretation by the user, as required for FDA approval.